Trials / Terminated
TerminatedNCT00299390
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer
Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as First Line Therapy in Chemotherapy Naive Patients With Extensive Disease (ED) Stage Small Cell Lung Cancer (SCLC)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the study drug is effective and safe in the first line treatment of patients with small cell lung cancer
Detailed description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sagopilone (BAY86-5302, ZK 219477) | Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2006-03-06
- Last updated
- 2015-12-31
Source: ClinicalTrials.gov record NCT00299390. Inclusion in this directory is not an endorsement.